The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma
- 1 February 1988
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 13 (11) , 574-577
- https://doi.org/10.1007/bf02574771
Abstract
MIBG is generating considerable interest for the treatment of neuroblastoma. This study has investigated the biological variation in handling of the compound in children with neuroblastoma. The biodistribution of the compound has been characterised in children undergoing tracer administrations of123I and131I-mIBG. Estimates of hepatic and whole body radiation dose delivery have been made. The results indicate substantial interpatient variation in hepatic dose delivery. This organ may be critical in some patients undergoing targeted radiotherapy with mIBG.This publication has 4 references indexed in Scilit:
- I-131 METAIODOBENZYLGUANIDINE FOR THE LOCATING OF SUSPECTED PHEOCHROMOCYTOMA - EXPERIENCE IN 400 CASES1985
- Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26.Journal of Clinical Oncology, 1984
- RADIOPHARMACEUTICAL TREATMENT OF MALIGNANT PHEOCHROMOCYTOMA1984
- RADIOLABELED ADRENERGIC NEURON-BLOCKING AGENTS - ADRENOMEDULLARY IMAGING WITH [I-131]IODOBENZYLGUANIDINE1980